On January 12, 2026 Amplia therapeutics reported interim data from Phase 2a ACCENT trial in metastatic pancreatic cancer has been presented at the 2026 American Society for Clinical Oncology: Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation, delivered by Amplia’s Chief Medical Officer Dr Jason Lickliter, highlights updated efficacy and safety data for narmafotinib in combination with standard chemotherapy (gemcitabine and AbraxaneÒ).

Key points from the poster include:

The updated progression-free survival (PFS) is 7.7 months, compared to 5.5 months for Gemcitabine and Abraxane alone

The overall response rate (ORR) is 35%; this increases to 42% when including unconfirmed responses

Narmafotinib continues to be well tolerated by patients with the adverse effect profile of the narmafotinib-chemotherapy combination similar to chemotherapy alone

Amplia CEO, Dr Chris Burns, commented:
"We are pleased to present our research findings to clinicians and scientists at this conference, one of the world’s premier pancreatic cancer meetings. Presenting at ASCO (Free ASCO Whitepaper) GI positions Amplia among leading biotechnology and pharmaceutical companies internationally and underscores the company’s exciting progress in the development of narmafotinib in pancreatic cancer."

(Press release, Amplia Therapeutics, JAN 12, 2026, View Source [SID1234661923])

On January 12, 2026 Swiss Rockets AG and Alloy Therapeutics, Inc. reported the signing of a Master Research Agreement (MRA) establishing a multi-target collaboration to discover and develop next-generation radioligand therapeutics (RLTs) for oncology. The collaboration will be executed through Swiss Rockets’ radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Radioligand therapeutics are an emerging modality that can deliver radiation directly to tumor cells via highly selective targeting agents. Under the MRA, Alloy will provide access to its proprietary antibody discovery and engineering platforms, while Swiss Rockets and Torpedo will apply their radioisotope and radiopharmaceutical development expertise – including the use of Terbium-161 – to advance prioritized targets toward clinical development.

Collaboration highlights:

Multi-target oncology collaboration spanning discovery, engineering, and radiopharmaceutical development.
Access to Alloy’s enabling technologies for antibody discovery and optimization to generate high-quality targeting agents.
Torpedo-led radiochemistry, isotope integration, and translational development to advance RLT candidates toward the clinic.
"This agreement reflects Swiss Rockets’ strategy to unite cutting-edge discovery technologies with our translational and radiotherapeutic expertise. Together with Alloy, we aim to accelerate the emergence of next-generation cancer therapies through scientific and entrepreneurial collaboration. It exemplifies how strategic partnership and scientific innovation can speed the development of transformative oncology medicines," said Dr. Vladimir Cmiljanovic, Chief Executive Officer of Swiss Rockets AG and Torpedo Pharmaceuticals AG.

"Radioligand therapeutics represent an exciting frontier in oncology, and this partnership reflects Alloy’s broader mission to democratize access to enabling technologies and work with founders advancing breakthrough science," said Errik Anderson, Chief Executive Officer and Founder of Alloy Therapeutics. "We’re excited to collaborate with Swiss Rockets and Torpedo to help build a robust radioligand therapeutics capability that combines our discovery platforms with their radiotherapeutic infrastructure to deliver meaningful innovation for patients."

The parties intend to apply this framework to generate novel RLT candidates for high-value oncology targets and to accelerate translation from discovery into development-ready programs.

(Press release, Alloy Therapeutics, JAN 12, 2026, View Source [SID1234661914])

On January 11, 2026 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Total revenues of approximately $660 million in the fourth quarter of 2025 compared to $476 million in the fourth quarter of 2024, an increase of approximately 39%. Total revenues, excluding revenue true-ups, were greater than $600 million.
Total revenues of approximately $2.3 billion in the full year 2025 compared to $1.7 billion in the full year 2024, an increase of approximately 35%.
Approximately 923,600 tests were processed in the fourth quarter of 2025 compared to 792,800 tests in the fourth quarter of 2024, an increase of 17%.
Approximately 3,525,500 tests were processed in the full year 2025 compared to 3,064,600 tests in the full year 2024, an increase of approximately 15%.
Approximately 233,300 oncology tests, including approximately 225,300 clinical molecular residual disease (MRD) tests, were processed in the fourth quarter of 2025 compared to 150,800 oncology tests, including 144,500 clinical MRD tests, in the fourth quarter of 2024, an increase of 55%.
Clinical MRD tests increased by approximately 22,800 tests in the fourth quarter of 2025 over the third quarter of 2025, representing a record sequential growth quarter. This tops the previous record set in the third quarter of 2025, despite fewer days to receive samples in the fourth quarter.
Approximately 800,800 oncology tests, including approximately 769,700 clinical MRD tests, were processed in the full year 2025 compared to 528,200 oncology tests, including 498,300 clinical MRD tests, in the full year 2024, an increase of 52%.
The Company achieved cash inflows of approximately $30 million1 in the fourth quarter of 2025 compared to approximately $46 million2 in the fourth quarter of 2024.
The Company achieved cash inflows of greater than $100 million1 in the full year 2025.
"2025 was a record year for oncology, organ health and women’s health," said Steve Chapman, CEO of Natera. "The fourth quarter was particularly strong, with excellent growth in volume, revenue and gross margins. We believe we are well positioned to continue building on this momentum in 2026 and beyond."

These results will be included in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 pm PT, and also posted to the investor relations section of the Natera website at www.investor.natera.com. Natera will also present additional business updates at the J.P. Morgan conference.

Natera plans to release its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026.

References

Non-GAAP cash inflow / outflow for the quarter and year ended December 31, 2025 is estimated based on estimated unaudited GAAP Statement of Cash Flows amounts including net cash from operating activities, net cash from investing activities excluding amounts related to short-term investments, and net cash from financing activities.
Non-GAAP cash inflow / outflow are calculated based on GAAP Statement of Cash Flows amounts including net cash from operating activities, net cash from investing activities excluding amounts related to short-term investments, and net cash from financing activities excluding proceeds from public offerings. Please refer to our website at www.investor.natera.com/financials for a reconciliation of non-GAAP cash inflow / outflow to the most directly comparable GAAP financial measure. Management uses non-GAAP cash flow as an indicator of the Company’s operational cash generating capabilities.

(Press release, Natera, JAN 11, 2026, View Source [SID1234661929])

On January 11, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported preliminary, unaudited results for the quarter and full year ended December 31, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth quarter 2025 preliminary unaudited financial results

For the three-month period ended December 31, 2025, as compared to the same period of 2024:

Total revenue of approximately $280 million, an increase of 39%
Reported approximately 79,000 oncology tests, an increase of 38%
Reported approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period
Full year 2025 preliminary unaudited financial results

For the twelve-month period ended December 31, 2025, as compared to the same period of 2024:

Total revenue of approximately $981 million, an increase of 33%
Reported approximately 276,000 oncology tests, an increase of 34%
Reported approximately 87,000 Shield screening tests
"2025 was a breakout year for Guardant, with total revenue growth accelerating to 33% year-over-year," said Helmy Eltoukhy, co-founder and co-CEO. "We saw exceptional volume growth in Oncology over the last year, primarily driven by pioneering innovation from our Smart Platform and best-in-class commercial execution. We expect this momentum to continue throughout the year with the launch of multiple groundbreaking products that will fuel the next phase of growth in our Oncology business."

"We are incredibly proud of Shield’s strong momentum as we continue to strengthen our leadership in the blood-based colorectal cancer screening market, with Shield positioned as one of the most successful diagnostic launches to date," said AmirAli Talasaz, co-founder and co-CEO. "Since FDA approval, nearly 100,000 patients have been screened with Shield. We have now expanded Shield to include multi-cancer detection findings, further enhancing the clinical value of the platform for both patients and physicians. Together, these milestones will further advance the fight against cancer in 2026 and beyond."

Preliminary unaudited free cash flow was approximately negative $54 million for the fourth quarter of 2025, and approximately negative $233 million for the full year 2025. Cash, cash equivalents, restricted cash, and marketable debt securities were approximately $1.3 billion as of December 31, 2025.

Guardant Health has not completed preparation of its financial statements for the fourth quarter or full year of 2025. The revenue, test volumes and free cash flow presented in this release for the fourth quarter and the year ended December 31, 2025, are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete our financial results. The company is in the process of completing its customary year-end close and review procedures as of and for the year ended December 31, 2025, and there can be no assurance that final results for this period will not differ from these estimates. During the preparation of Guardant Health’s consolidated financial statements and related notes as of and for the year ended December 31, 2025, the company’s independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.

Upcoming events

Guardant Health plans to report its fourth quarter and full year audited financial results for the period ended December 31, 2025, during its February 2026 earnings call.

(Press release, Guardant Health, JAN 11, 2026, View Source [SID1234661928])

On January 11, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full Year 2025 Select, Preliminary, Unaudited Financial Results

Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth (excluding Ambry)
Diagnostics revenue of ~$955 million, representing ~111% growth year-over-year, driven by Oncology volume growth of ~26% and Hereditary volume growth of ~29%
Data and applications revenue of ~$316 million, representing ~31% growth year-over-year, driven by ~38% growth in Insights (Data Licensing)
Fourth Quarter 2025 Select, Preliminary, Unaudited Financial Results

Revenue of approximately ~$367 million, an increase of approximately 83% year-over-year
Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth of ~29% and Hereditary volume growth of ~23%
Data and applications revenue of ~$100 million, representing ~25% year-over-year growth, with Insights growing ~68%, excluding the impact of the AstraZeneca warrant in Q4 of 2024.
"2025 was an exceptional year for Tempus with the strength of both of our product lines exceeding our initial expectations for the year," said Eric Lefkofsky, Founder and CEO of Tempus. "Within Diagnostics, year-over-year volume growth of our genomics (oncology) offering accelerated for the third consecutive quarter hitting the highest unit growth rate we have seen in years. Our Data and Application business is performing even better with record revenue of ~$100 million in the fourth quarter, achieving full-year growth of ~31%, with our data licensing business growing ~38%. We enter 2026 in an exceptionally strong position with both of our main businesses accelerating in growth and delivering the financial leverage inherent in our platform. With AI as a catalyst across all of our products, we couldn’t be more excited for 2026."

This announcement comes ahead of the Company’s presentation today at the 44th Annual J.P. Morgan Healthcare Conference. A live webcast of the presentation and our updated investor deck can be found on Tempus’ investor relations website at investors.tempus.com.

Tempus has not completed preparation of its financial statements for the fourth quarter or full year 2025. The estimates disclosed in this release for the fourth quarter and year ended December 31, 2025, are preliminary, and unaudited and inherently uncertain, and therefore subject to change as Tempus completes preparation of its financial results for these periods. Tempus is in the process of completing its customary year-end close and review procedures for the quarter and year ended December 31, 2025, and there can be no assurance that final results for these periods will not differ from these estimates, and any such difference may be material. During the preparation of Tempus’ consolidated financial statements for the year ended December 31, 2025, Tempus or its independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.

Tempus plans to report its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026.

(Press release, Tempus, JAN 11, 2026, View Source [SID1234661927])